With 0.77 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.57 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $4.22 whereas the lowest price it dropped to was $3.72. The 52-week range on NXL shows that it touched its highest point at $4.36 and its lowest point at $0.25 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 3.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NXL was down-trending over the past week, with a drop of -0.77%, but this was up by 75.00% over a month. Three-month performance surged to 313.98% while six-month performance rose 470.62%. The stock gained 1045.83% in the past year, while it has gained 851.09% so far this year.
Float and Shares Shorts:
At present, 12.86 million NXL shares are outstanding with a float of 9.82 million shares on hand for trading. On 2024-10-15, short shares totaled 93398.0, which was 88.0 higher than short shares on 1726185600. In addition to Mr. Mark White as the firm’s President, CEO, CFO & Director, Dr. David Owens M.D. serves as its Chief Medical Officer & Director.
Institutional Ownership:
Through their ownership of 0.0241 of NXL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, NXL reported revenue of $36031.0 and operating income of -$2508517.0. The EBITDA in the recently reported quarter was -$2560555.0 and diluted EPS was -$0.23.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NXL analysts setting a high price target of 3.0 and a low target of 3.0, the average target price over the next 12 months is 3.0. Based on these targets, NXL could drop -22.08% to reach the target high and fall by -22.08% to reach the target low. Reaching the average price target will result in a decline of -22.08% from current levels.
Analysts have provided yearly estimates in a range of -$0.49 being high and -$0.49 being low. For NXL, this leads to a yearly average estimate of -$0.49.
